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Mean plasma lipid values in 100 patients who survived >3 months
after heart transplantation increased significantly at 3 months
over prelransplantation values : total cholesterol from 160 ± 7 to
234 *_ 7
mg/dl,
low density lipoprotein (LDL) cholesterol from
111 t 6 to 148 ± 6 mg/dl, high density lipoprotein (RDLI
cholesterol from 34 t I to 47 t I mg/dl and triglycerides from
107
a
6 to 195 t 10 mg/dl . There were no significant increases
after this time
. The LDL cholesterol values remained > 130 mg1dI
In 64% of patients and triglyceride values remained >200 mg/dl
In 41% of patients 6 months after postoperative dietary instruc-
tions.
Beginning in 1985, select patients whose total dtolesterot values
remained >300 mg/dl despite 6 months of dietary intervention
were treated with lovastatin given alone in a high dose (40
to
80 mglday) or in combination with another hypolipidemic agent .
Four of the five patients so treated developed rhabdmnyulysis ; two
of the four had acute renal failure. Beginning in 1988, a second
Guidelines for the pharmacologic treatment of hypertipi-
demia have evolved over the last 2 decades an the basis of a
wealth of clinical information . The most recent recommen-
dations of the National Cholesterol Education Program 11) in
the United States were formulated by a panel of experts to
allow physicians to optimize the benefits of treatment while
minimizing its risk. However, treatment of hyperlipidemia
after heart transplantation may require different guidelines
because of the different risk/henefit ratio in these patients .
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prolocoHovastatin at 20 rog/day as amam0erapy-was used in
patients who despite dietary intervention had total cholesterol
>240
mg/dl (mean follow-up 13 monlki) . In the 15 patients so
treated, mean total cholesterol decreased from 299 t 10 mg(dl
before treatment with lovastatin
to 235 ± 9
rag/dl
daring treat.
metal, (21 % reduction, p < 0.001) and mean LDL cholesterol was
reduced from a baseline value of 190 a 10 to 132 = 12 mg/dl
during treatment (31% reduction, p < 0 .001) .
In this study, lovastatin at a dose of <<20 mg/day as monother-
apy was a well Initiated
. eQeelive treatment for hypaBpalemia
after heart transplantation. D did not result is rhabimyalysi
and required no Attention in le.mnaaomppeeseive therapy- How-
ever, the dose should not eseeed 20 day and comhinafam
therapy with either gemibroell or rrotiaic arid should be
avoided, even if the target
LDL cholesterol value is not reached.
(J Am Coll Card
W 1992
:19:1315-21)
Although heart transplant recipients have extraordinarily
high rates of both hyperlipidemia and accelerated coronary
artery disease, the adverse side effects from hypolipidemic
agents are increased and the benefits of therapy must be
considered untested because of the unique palhophysiology
of coronary artery disease in the attograft „earl (2).
In this report, we describe a 6-year experience using
lovastatin, a competitive inhibitor of 3-hydroxy-3-
methylglutaryl coenzyme A reductase. to treat dyslipidemia
after heart transplantation . In addition, we examine the
frequency and pattern of dyslipidemia in all heart transplant
recipients at one of our institutions during this period,
review the available data on the risks and benefits of the
various lipid-lowering agents in the context of heart trans-
plantation and provide treatment recommendations on the
basis of these data.
Methods
Patients and laboratory assessments . From September
1985 to March 1990, 100 patients underwent orthotopic heart
0737-109719215`.00
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transplantation at The Methodist Hospital and survived
>3 months. All patients received immunosuppressive ther-
apy with prednisone and cyclosporine ; 82% w.-re also
treated with azathioprine. Venous blood samples taken alter
fasting were obtained before transplantation and at intervals
of I, 3, 6 and 12 months after transplantation . Plasma total
cholesterol, high density lipoprotein (HDL) cholesterol and
triglyceride levels were measured by standard laboratory
methods as previously described (3) . Low density lipopro-
tein (LDL) cholesterol values were estimated by the formula
of Friedewald e! al . (4) . All patients were given instructions
on the American Heart Association Step One Diet before
discharge from the hospital after heart transplantation . In
select cases, total 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitory activity was measured with use of a
Merck Laboratories in vitro bioassay system .
Treatment protocols . During the I st 2 years of the study
(1985 to 1987), five select patients who had two or more
consecutive total plasma cholesterol readings >300 mg/dl
despite dietary intervention for 6 months after transplanta-
tion were treated with high dose lovastatin or lovastatin
combined with another lipid-lowering agent . Lovastatin
therapy was begun at a dose of 20 mg oraiiy ace a day in the
evening, then increased to a maximum of 40 mg orally twice
a day or given in combination with a second drug, or both .
Lipoprotein, hepatic transaminase . serum creatine kinase
and whole blood cyclosporine levels (measured by radioim-
mttnoassay) were determined every 6 weeks during lovasta-
tin treatment .
This pm,!oco! (prolorol i) of high dose (w40 mg/day)
lovastatin or combined therapy was effective (5) . However,
the protocol-particularly the approach of using a combina-
tion of drugs-caused an unacceptably high incidence of
myositis (6,7) . Therefore, since 1988, both The Methodist
Hospital and The Texas Heart Institute have used monother-
apy with lovastatin at 20 mg/day (protocol 2) in select
heart transplant recipients with plasma total cholesterol
>240 mg/dl on two or more consecutive measurements made
after 6 months of dietary therapy . The change in the total
cholesterol value used as a threshold for treatment was made
after the appearance of the National Cholesterol Education
Program adult treatment guidelines (1) .
Protocol I was approved as a "compassionate use"
protocol. Protocol 2 was approved by the Institutional
Review Board of each institution .
Statistical analyses. Results are expressed as mean values
t SEM . In the natural history analyses, changes in lipid and
lipoprotein levels between baseline and subsequent mea-
surements were evaluated by using analysis of variance
(ANOVA) and the Bonferroni method . A paired Student
I test was used to assess changes in the treatment group in
lipoprotein levels and other laboratory measurements, un-
less abnormal distribution was present, in which case a
paired Wilcoxon signed-rank test was used .
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Figure 1 . Mean plasma lipid values (_<SEM) in 100 patients before
and after heart transplantation . All patients received dietary instruc-
lion after transplantation : none was yet receiving a lipid-towering
agent. Baseline versus 3-month values are significant al p < 0 .05 for
both total cholesterol and Iriglycerides .
Results
Natural History Study
The patients were 91 men and 9 women, ranging in age
from 15 to 68 years (mean 49). Changes in lipid and lipopro-
tein values after heart transplantation in these patients are
shown in Figures 1 and 2 . All changes in these values
between baseline (before transplantation) and 3 months after
transplantation were significant at p < 0 .05 .
Total cholesterol increased from 168 w 7 mg/dl at baseline
to 211 t 6 mg/dl at I month and to 234 ± 7 mg/dl at 3 months .
Triglycerides showed a similar pattern of change, with an
increase from 107 ± 6 mg/dl at baseline to 150 t 7 mg/dl at
I month and to 195 ± IO mg/dl at 3 months . High density
lipoprotein cholesterol increased from a baseline value of
34 ± I mg/dl to a peak of 56 ± 2 mg/dl at I month with a
decline to 47 ± I mg/dl at 3 months . In the subset of
56 patients whose HDL cholesterol level was measured at all
Figure 2 . Mean plasma lipoprotein values (tSEM) before and after
heart transplantation in the m0 patients. Baseline versus 3-month
values am significant at p < 0 .05 for both high density lipoprotein
(HDL) cholesterol and low density lipoprotein (LDL) cholesterol .
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time points, the increase that occurred between baseline and
I month and the decline that occurred between I and
3 months were significant (p < 0.001 and p < 0 .005
.
respectively). Low density lipoprotein cholesterol increased
from Ill ± 6 ntg/dl at baseline to 124
.
5 mg/dl at I month
and to 148 ± 6 mg/dl at 3 months . No further significac
changes in lipid or lipoprotein values occurred after 3
months .
Despite the postoperative instructions given patients re-
garding the American Heart Association Step One Diet.
LDL cholesterol remained 8_130 mg/dl in 64% of patients
and v 160 mg/dl in 22% at 6 months after transplantation
. In
addition, triglycerides remained ?200 mg/dl in 41% or pa-
tients and >250 mg/dl in 23% at this time .
Treatment Protocols
Protocol 1. We treated five patients with high dose lov-
astatin or lovastatin combination therapy. Although initially
we reported (5) substantial reductions in levels of LDL
cholesterol with lovastatin at a dose of 40 mg orally twice a
day, we subsequently encountered severe toxicity rhabdo-
myolysis (6,7). Relevant clinical and laboratory data on the
four patients who experienced unacceptable toxicity while
receiving lovastatin at a high dose (40 mg orally either once
or twice daily) or as part of combined hypolipidemic therapy
are shown in Table l . Elevations in creatine kinase and
P
reviously described (6.7).
4Delermined C h after dose by whole blood mdioimmunoassay. ALP = alkaline plosphatase : ASCVD = atherosclerotic
cardiovascular disease: AST = aspartate amieotransferase ; b .i .d. = twice daily : Dili = total bilimbin: CK = crealita kinase
: CR = creatinine: F = female:
,CM = idiopathic cardiomyopathy
: M = mats q.d . = every day: TC = total cholesterol 1, d. = three times daily : W = white.
measures of liver function are apparent. Two of the patients
had acute renal failure. Three of the four were receiving
combination hypolipidemic therapy
. The second agents
used-nicotinic acid . gemfibrozil and the antibiotic erythro-
mycin-are all now known to interact with lovastatin and
increase the likelihood of rhabdomyolysis
; with respect to
nicotinic acid, enhanced hepatic dysfunction may also oc-
cur.
Total 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitory activity in plasma was measured at the time of
rhabdomyolysis in two of the five patients. In one (Patient l,
Table 1) . the activity was 310 ng-equivalentslml 12 h after the
second daily dose of 40 mg on day l . In the other (Patient 2,
Table 1) . the activity was 251 ngequivalentslml 3 h after the
second daily dose of 40 mg of lovastatin given on day I . Both
values are markedly increased compared with the mean
maximal inhibitory activity of i9 .9 ± 2 .3 ng-equivalentslml
seen with high dose lovastatin (20 me twice daily) in hyper-
cholesterolemic patients not receiving immunosuppressive
therapy (8). When the two patients were rechaltenged with
only a single daily dose of 20 mg of lovastatin, the inhibitory
levels decreased to 65 and 87 ng-equivatents/ml, respec-
tively, 4 h after the dose (substantial improvements, but still
higher than the published control values with the drug at
40 mg/day [81) .
Protocol 2. Fifteen patients began lovastatin treatment on
protocol 2 lmonotherapy with lovastatin at 20 mg/day), in
1988 or later. Among the 14 men and I woman (mean age 54
JACC Vol. 19. Nn. 6
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Table 1 . Clinical/Laboratory Characteristics of Patient-: With Uracceplahic Toxicity From High Dose 1040
mg/day)
or Combination
Lovastatin Therapy (protocol I . n = 5)
Patient
P
Patient
71
Patient
3
Patient
4
Age (yrllrecelgender
3&W M
46 .W',17
321W/F 4TW M
Reason for transplantation
Lovastarin
Dose (mgilschedule
Dumnonlmol
ASCVD
401b .i .d.
9
ASCVD
41Ph.i .d.
I6
ASCVD
4@q d.
8
ICM
SOq
.d.
to
Other medication-doslschedule
Cyelosparine Imglkg)
, 'Id . 41q.d . 4/q.d .
Aeathioprine Imgl
1251q.d .
Pmchiiscme lingo 0,'A' 1109 4
. IWq.d . Wit d .
Gemfibrozil Imgl
600/b.1d.
Nicotinic acid. slow release (mg)
Erythromycin Ig)
Sersmiplasma values
TCimr/dth-beforelmi1-estetin 359!237
Tq .d .
/10,: , 51
SOWLi .d .
3681290 2'U217
AST lUnitori 266 843 397
ALP (1-111i.0 52 Ch 155 SI
Dili mg/dl) 0.9
0.9 3.3 0 .5
CK Miter) 8920
23
.812
1,122 12 .090
CR (mg/dl) 9.7 2 .8 2
.1 9
Cyclosporiner lnglml) 1 .013 9114
908 -
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Table 2 . Mean Lipid, Lipoprotein and Other Laboratory Values
Before and During Treatment With Lovaslatin Monothenlpy at
20 mg/day (protocol 2, 1i = 15)
ALT= alalne amionlrunsterase: BUN = blood ur nitrogen
: Cydo =
cydosporhle: HDL-C = high density lipnpnaetn cholesterol . LOU = Iaclale
dehydrogenate: LDL-C
-
low density ItpProtein c691nterol: TG = Iriglyc.
eetdes: WBC = white blood cells: other nhhrevialions nr in Table I .
years), the cause of heart failure was coronary artery disease
in I I and idiopathic cardiomyopathy in 4 . Mean follow-up
after the initiation of lovastatin treatment was 13 months
(range 6 to 301. All patients were explicitly warned to
discontinue lovastatin and to have their serum creative
kinase level determined if muscle soreness developed .
The effects of lovastatin on plasma lipids and lipoproteins
and other laboratory values in patients on protocol 2 (mean
values determined at 6 to 12 weeks) arc shown in Table 2 .
Total cholesterol decreased from 299
„
10 mg/dl before
treatment to 235 '- 9 mgldl during treatment (21% reduction .
p < 0
.001). Low density lipoprotein cholesterol was reduced
from 190 ± 10 mgldl before treatment to 132 ± 12 mg/dl
during treatment (31% reduction . p < 0.001). Favorable but
statistically insignificant changes were also noted between
baseline and treatment measurements of triglyceride and
HDL cholesterol levels
.
The increase in total bilirubin was of borderline statistical
significance and was not considered to be clinically mean-
ingful. The mean plasma cyclosporine level did not change
significantly
. The mean creatine kinase value with treatment
was 93 U/liter (range 41 to 245: normal 35 to 200) . One
patient reported muscle soreness and discontinued lova-
statin therapy without having the creatine kinase level mea-
sured
. She was rechallenged with lovastatin at 10 mg/day
and again reported vague muscle soreness
: the creating
kinase measurement was 56 U/liter (within normal limits) at
the 10-mg doss
.
Treatment with the low dose lovastatin protocol did not
require significant alterations in daily doses of cyclosporine .
prednisone or azathioprine
. No other side effects were
observed with protocol 2 .
tACC Vnl. 19 . Nn. R
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Discussion
Postulated mechanisms or hyperlipidemia after transplan .
tation . The high prevalence of hyperlipidemia observed in
our patients is consistent with data in previous studies
15
.9-13) examining the natural history of lipid changes after
heart transplantation . One mechanism that has been pew
posed to account for the high incidence of dyslipidemia after
heart transplantation is correction of severe congestive heart
failure in patients with preexisting lipid abnormalities . In
many of cur patients with severe congestive heart failure and
a history of hyperlipidemia, total cholesterol values were
depressed before transplantation .
A seronrt proposed me<hnrlistn is the use of imm uno-
suppi t aoive drags. Several series 114-161 have demonstrated
increased levels of total cholesterol after the administration
of cyclosporine . The total cholesterol elevations were pri-
marily the result of elevations of LDL cholesterol (5)
.
Prednisone has been shown to increase both total and HDL
cholesterol values in heart transplant recipients (17,18). In
our series, HDL cholesterol was significantly increased at I
month after transplantation and the decline at 3 months
coincided with tapering of prednisome dosage
. Taylor et al .
(19) observed that heart transplant patients who received
only azathioprine plus cyclosporine as immunosuppressive
therapy did not show an increase in HDL cholesterol . The
increase in HDL cholesterol is primarily the result of an
increase in the HDL, subtraction, including an increase in
apolipoprotein A-I 120.21) . Lipoprotein lipase activity was
inversely related to cyclosporine levels in one study 1221 of
heart transplant recipients . and low levels of lipoprotein
lipase activity may lead to increases in plasma triglycerides.
The posuransplantalion increase in plasma triglycerides in
our patients may also be related to the administration of
cyclosporine .
Indications for treatment. The sequence of the lipid
changes observed in our patients suggests that clinical as-
sessment for hyperlipidemia should be performed 3 to 6
months after transplantation . Lipid values did not signifi-
cantly change during the 3 months in which the patients were
asked to comply with the American Heart Association Step
One Diet as recommended by the National Cholesterol
Education Program (I)
.
The algorithm of the National Cho-
lesterol Education Program for deciding to pharmacologi-
cally treat elevated cholesterol is based on both the LDL
cholesterol value and the total risk for developing coronary
artery disease . Accelerated coronary artery disease is the
most common cause of graft failure in long-term survivors of
heart transplantation and is present in 30% of patients by 28
months (23 .24): therefore, any heart transplant recipient
regardless of gender or traditional risk factors should be
considered to be at high risk for developing coronary artery
disease
. The National Cholesterol Education Program guide-
lines (1) suggest that drug treatment he considered in high
risk patients when the LDL cholesterol value remains
?160 mg/dl after 6 months of dietary therapy . By that
Batchne I realmem
Change
1%; pTulue
TC Imgldl) 299 20 -21
<0uH11
TG Imgldlr 297 773 NS
LDL-C Imp/dl) 1911 132 <11 ./511
HDL.C Img/dll 39 42 NS
ASTIU/lilerl 23 21 9 NS
ALT 1U/Alert 23 18 NS
LOU 9/liter) 185 173 -6 NS
ALPIU/lilerl 114 115 +11.9 NS
Bill (m g
/dll
0.67
(1.51
+27
ILm
CK (tllliler) - 93
BUN ImgJdi)
31 35 +13 NS
Cyclo Idosc in mgt 263 296 +10 NS
WBClerIL1109mm'1 6 .4 7
.3
+14
NS
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Table 3
. Special Considerations in the Use of Lipid-Lowering Drugs After Heart Tr.-plantation
Drug
PosvMe Side Effect,
nicer ctiuns With imurua-rpre,ant,
Bile acid eeyucstranl MayV-- ehsarp'ian 4 17", vlnhlc drag, ; Mror
lchoteslyramine
. cole.vipoll compliance because of constipation and hloaling
Nicotinic acid Elevation
of liver funainr lasts, increased uric acid
ivvrl . dccrca .d glu<o,e mlcranve ~mcerM1anion of
Peptic ulcer docare
Fibric acid derivative Igemfibrozill Gallstone myu,itis
: mmsea pot<otimioo of
-,fu-in
criterion
. 22% of the patients in our natural history series
would be considered eligible for pharmacologic intervention
.
In addition to the high frequency of LDL cholesterol
elevation among our patients 164% had LDL cholesterol
?130 mgldl at 6 months), we noted a high incidence of
elevated triglyceride levels (41% had Iriglyceride values
0_200 mg/dl at 6 months) .
Deciding whether to apply the National Cholesterol Ed-
ucation Program guidelines to heart transplant recipients
hinges on whether the benefits of lowering lipids are greater
than the toxicity of treatment . The role of hyperlipidemia in
the development of accelerated coronary artery disease
remains controversial (9 .23-26) . The diffuse intimal prolifer-
ation that occurs after heart transplantation is pathologically
unique and is believed to be an immunologically mediated
form of chronic rejection
. Although lipopro!eies probably do
not play a primary role in the development of this disorder,
both clinical and animal studies (9,25,26) suggest that hyper-
lipoproteinemia may accelerate the process. Prospective
clinical trials to examine whether the treatment of hyperlip-
idemia will indeed slow the process of postlransplantation
intimal proliferation have not been performed .
Dietary modification is the safest form of treaunent for
hvperlipidemia . All the patients in our series received di-
etary counseling to follow the American Heart Association
Step One Diet . Dietary intervention has been shown to have
beneficial effects on blood lipid levels after renal transplan-
tation (27-30), but the reductions have been modest and
many of the patients have had persistent elevations ofLDL
cholesterol and triglycerides
. This was also the characteris-
tic pattern in our heart transplant recipients . Because both
thiazida ciuteiics and nonselective beta-adrenergic blockers
may elevate lipid values, we avoid prescribing these agents
as antihypertensive therapy after heart transplantation . Dis-
continuing prednisone or reducing its dose may also amelio-
rate hyperlipidemia (17-19), but with the possibility of in-
creasing the risk of allograft rejection
. Therefore, despite
dietary intervention and optimization of medical manage-
ment. many patients will still have elevated cholesterol or
triglyceride levels and require pharmacologic intervention .
ISIS
.`day iabibit abwrptice of gclosporina,
winch,
extremely fat soluble
C'yelusprrtc may cause etevatinns of liver fnnetiun test,
and uric acid levels
; predniwne aecrea+e+glucasa
lokrnce and may Was— m
peptic elect Jeease
Increased myosi is with coneceitant lovadatin +
immunosuppressive drags : decreased metabolism in
renal failure
Drug Treatment of Hvper(ipidemia After Heart
Transplantation
The potential side effects and drug interactions of lipid-
lowering agents must be weighed carefully in the setting
of
heart transplantation (Table 3)
.
Bile aciu sequestranis (cholestyramine and colestipul in the
U .S.) . These a considered first-line drugs for treatment of
elevated choiasterol by the National Cholesterol Education
Program Expert Panel (I) because they have been shown to
reduce the incidence of coronary artery disease end points
with a low incidence of toxicity
. In addition to causing
constipation, bile acid resins may interfere with the absorp-
tion of lipid-soluble drugs such as cyclosporine
. Keogh et al.
(31) used cholestyramine in five patients after heart trans-
plantation and achieved a modest (14%) reduction in total
cholesterol
. Poarmacokinetic studies measuring the area
under the whole blood cyclosporine concentration time
curve in this study showed variable results, from a 23%
decrease to a 55% increase from baseline . Bile acid-binding
resins may raise triglyceride levels, which frequently are
already elevated after heart transplantation
. Because of the
potential adverse effects on the absorption of immunosup-
pressive drugs and on triglyceride metabolism, we do not use
bile acid-binding resins as first-choice monotherapy after
cardiac transplantation . However, in reduced doses and
given either I h after or4 h before the administration of other
medications . these agents may be useful in combination with
other lipid-lowering drugs .
Nicotinic acid. This agent is also considered a first-line
drug for the treatment of high cholesterol by the National
Cholesterol Education Program because of documented ben-
efit on coronary artery disease reduction and an acceptable
rate of side effects . Nicotinic acid has the advantage of
beneficial effects in the mixed hyperlipidemia pattern that is
frequently seen after heart transplantation . Unfortunately,
nicotinic acid entails numerous side effects potentially exac-
erbated by immunosuppressive therapy . Both nicotinic acid
and cyetosporine can lead to increased values in liver
function tests and elevations of uric acid levels (32,331. Both
3-Hed,euy-3-melhylglcieryi
Elev :neon of h ;m,ammmc ladv. m . loop Cydosponec
may increase hear function lest . : greasy
-nzyme A reductase inhibitor dismrhance,
reused myu,iti, risk with lovaelatin +
ttoVantatinl
Immune . cp essive drugs lcydwparicet
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nicotinic acid and prednisone are associated with abnormal-
ities of glucose tolerance and exacerbation of peptic ulcer
disease . Because of the potential increase in side effects u:
heart transplant recipients, we believe that nicotinic acid
may not be a first-line agent and should be used with caution
in these patients.
Cemflbrozil, a fibric acid derivative . This is another drug
that has been show,: !o reduce the incidence of coronary
artery disease end paints (34) . Fibric acid derivatives reduce
triglyceride levels, with more modes) effects on LDL cho-
lesterol . We have used gemfibrozil as a single hypolipidemic
agent in a small series of heart transplant patients and
achieved marked reductions in triglycerides and more mod-
est reductions in total and LDL cholesterol levels (data not
shown). The drug is well tolerated in transplant patients and
has not been noted to interfere with immunosuppressive
therapy . Fibric acid derivatives have been associated with
an increased risk of gallstones, a finding of particular con-
cvrn because of the high incidence of cholelithiasis requiring
cholecystectomy among transplant recipients (35) . In addi-
tion, the modest LDL cholesterol-reducing effects of gem-
fibrozil limit its utility for treating severe hypercholesterol-
emia after heart transplantation .
Probucot- This agent causes a modest reduction in total
and LDL cholesterol values, but it has not been proved to be
effective in reducing coronary artery disease end points in
clinical trials
. When used by Anderson and Schroeder (36) in
heart transplant recipients, prubacol was well tolerated and
yielded a 15% reduction in both LDL and HDL cholesterol
values but no significant change in the ratio of LDL to HDL
cholesterol . The investigators noted no adverse clinical or
laboratory effects or interference with immunosuppressive
therapy . Probucol is unique among available lipid-lowering
agents in that it inhibits the oxidation of LDL particles .
Although this action theoretically can decrease LDL uptake
in the arterial wall, there are no published clinical trials to
confirm the benefit . We do not consider prbucol to be
first-line therapy, primarily because of its modest effects on
lipids
.
Lovastatin. The 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors as monotherapy have not yet been
shown to reduce the incidence of coronary artery disease
end points. In clinical studies (37-40), lovastatin therapy has
resulted in marked reductions in LDL cholesterol, ranging
from 24% to 40%, as well as reductions in triglycerides and
increases in HDL cholesterol
. Its major side effects are dose
dependent, including low rates of myositis (0 .5%) and serum
transaminase elevation (1
.5%) at the highest dose of
80 mg/day (37) .
As reported here, we initially used up to 80 mg/day of
lovastatin. At these high doses, our heart transplant recipi-
ents, who were receiving cyclosporine and prednisone, had
an unacceptable incidence of myosttis, as has been the expe-
rience of other groups (41,42). The increased toxicity in trans-
plant recipients may be explained by a marked increase in
plasma 3-hydroxy-3-methylglutaryl coenzyme A reductase in-
JACC V.I. 19, No. 6
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hibitory activity, an effect noted in our two patients in whom
inhibitory levels were measured after the occurrence of rhab
domyolysis . Although reduction of rho, daily dose
to 20 mg
reduced the enzyme inhibitory levels in these two patients,
the values were still greater than those that would he
expected in control subjects receiving the same dose of drug .
Similar findings were reported by Kobashigawa et al . (43).
Our treatment of 15 patients with a single daily 20-mg
dose of lovasratin resulted in a 21% reduction in total
cholesterol and a 31% reduction in LDL cholesterol . These
reductions are similar to those seen by others (42,43) using
low dose lovastatin after heart transplantation . Lovastatin at
20 mg/day was well tolerated by our patients, without
significant change in the mean level of cyciosporine in the
blood or in the doses given of cyclosporine, prednisone or
azathioprine
. The medication was discontinued in only I of
the 15 patients
. Our patients did not have the significant
increase in white blood cell count noted by Kasiske et al .
(44) in their lovasratin-treated kidney transplant recipients,
but the count did increase by 14% (from 6 .400 ± 600
cells/mm' at baseline to 7,300 ± 500 cells/mm' with Lova-
statin, p = NS).
Recommendations
. Lovastatin at a dose of 20 mg/day is a
well tolerated and effective treatment for hypercholesterol-
emia after heart transplantation . The dose should not exceed
20 mg/day-even if the desired level of LDL cholesterol is
not reached-because of increased drug toxicity in heart
transplant recipients . Combining lovastatin with gemfibrozil
or nicotinic acid should be avoided because this approach is
associated with enhanced toxicity .
Because of the increased toxicity of lipid-lowering drugs
in heart transplant recipients and the uncertain role of lipids
in the development of accelerated coronary artery disease in
the allograft, we believe that the National Cholesterol Edu-
cation Program treatment guidelines are not entirely appro-
priate for the heart transplant recipient with regard to drug
selection and treatment goals . Lovastatin in a low dose
(520 mg/day), with careful patient instruction and follow-up,
appears to be more effective and potentially safer than high
dose cholestyramine or nicotinic acid for treatment of ele-
vated LDL cholesterol in these patients. gemfibrozil is a
well tolerated and effective option for treatment of hyper-
triglyceridemia in these patients
. The National Cholesterol
Education Program goal of an LDL cholesterol level
<130 mgldl may be difficult to achieve with monotherapy,
and the data are insufficient to warrant aggressive combina-
tion therapy to reach this goal
. Prospective clinical trials are
needed to examine whether appropriate treatment of hyper-
lipidemia after heart transplantation can slow the develop-
ment of accelerated coronary artery disease in the allograft .
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